Chronic Wounds2019-10-07T12:42:45+00:00

Tackle the underlying issues that disrupt
the wound healing process.

You spend countless hours treating chronic wounds—diabetic ulcers, venous ulcers, pressure injuries. Called the “silent epidemic,” chronic wounds often result in infection, disability and sometimes amputation.1

Crafting the right treatment plan—one that addresses the individual needs of each wound and each patient—hinges on managing the underlying issues that can disrupt healing and increase healthcare costs:

Multiple health complications.

Chronic conditions (diabetes, venous disease, obesity); medications (steroids, NSAIDs, anti-rejection drugs); and lifestyle habits (smoking, alcohol abuse) make it more difficult for wounds to heal.2

Painful infections.

Bacteria and necrotic debris interfere with new tissue and blood vessel growth, stalling the healing process.2

Microscopic biofilm.

More than 90% of chronic wounds contain biofilm—complex colonies of bacteria and fungi that impair healing.3,4 Biofilm prolongs inflammation, elevates protease levels and increases exudate and fibrinous slough.4 Removing biofilm is difficult because it firmly adheres to surrounding tissue and is resistant to many antibiotics.4

Innovation in wound bed preparation and tissue regeneration brings new hope for these patients—and your team—in the form of more effective wound closure, improved quality of life and reduced costs.

, Chronic WoundsTransformations

, Chronic Wounds

“My team called it a wow moment.”

Lee C. Routsi, MD, ABWMS, CWS-P, UHM

Hear the story of a 52-year-old patient with a 3-year history of VLUs.
Watch video

Bring down barriers
to healing.

, Chronic Wounds

Learn more

Restart stalled wounds with PluroGel. This highly concentrated surfactant removes necrotic debris, hydrates tissue and helps you prepare a stable, healthy wound bed that enables healing.

Reset the wound
healing process.

, Chronic Wounds

Learn more

Use the unique cellular recruitment benefits of hyaluronic acid to drive a productive inflammatory response that leads to proliferation.5 Hyalomatrix helps you rebuild a well-vascularized neodermis suitable for re-epithelialization or autografting.6,7,8,9

Make the impossible
possible.

, Chronic Wounds

Learn more

Coming soon: New skin harvesting and transferring technology that enables full-thickness grafting in an outpatient setting with minimized donor site concerns.10,11

, Chronic Wounds Thought Leadership

, Chronic Wounds

Read now

A new study suggests that clinic-based sharp debridement has little impact on bacteria.12

, Chronic Wounds

Read now

Explore consensus guidelines for recognizing biofilms in chronic wounds and managing patients optimally.4

©2018 Medline Industries, Inc. Corius is a trademark and Medline is a registered trademark of Medline Industries, Inc.

1 Zhao R, Liang H, Clarke E, Jackson C, Xue M. Inflammation in Chronic Wounds. Intl Jour of Molecular Sciences. 2016;17(12):2085. Available at: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5187885/ . Accessed June 18, 2018.
2 Thomas Hess C. Checklist for Factors Affecting Wound Healing. Advances in Skin & Wound Care. 2011;24(4):192. Available at: https://journals.lww.com/aswcjournal/Fulltext/2011/04000/Checklist_for_Factors_Affecting_Wound_Healing.10.aspx . Accessed onJune 18, 2018.
3 Attinger C, Wolcott R. Clinically Addressing Biofilm in Chronic Wounds. Advances in Wound Care. 2012;1(3):127-132. Available at: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3839004/ . Accessed June 18, 2018.
4 Schultz G, Bjarnsholt T, James GA, et al. Consensus Guidelines for the Identification and Treatment of Biofilms in Chronic Nonhealing Wounds. Wound Repair and Regeneration. 2017;25(5):744-757. Available at: https://onlinelibrary.wiley.com/doi/epdf/10.1111/wrr.12590 . Accessed June 18, 2018.
5 Pasquinelli G, Vinci MC, Gamberini C, et al. Architectural Organization and Functional Features of Early Endothelial Progenitor Cells Cultured in a Hyaluronan-Based Polymer Scaffold. Tissue Eng Part A. 2009;15(9):2751–62.
6 Simman R, Mari W, Younes S and Wilson M. Use of Hyaluronic Acid-Based Biological Bilaminar Matrix in Wound Bed Preparation: A Case Series. ePlasty. 2018; 18:e10. Available at: http://www.eplasty.com/index.php?option=com_content&view=article&id=1924&catid=15&Itemid=116 . Accessed June 18, 2018.
7 Erbatur S, Coban YK, Aydın EN. Comparision of Clinical and Histopathological Results of Hyalomatrix Usage in Adult Patients. Intl Jour Burns and Trauma. 2012;2(2):118-125. Available at: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3462522/ . Accessed June 18, 2018.
8 Caravaggi C, Grigoletto F, Scuderi N. Wound Bed Preparation With a Dermal Substitute (Hyalomatrix® PA) Facilitates Re-epithelialization and Healing: Results of a Multicenter, Prospective, Observational Study on Complex Chronic Ulcers (The FAST Study). WOUNDS 2011;23(8):228–235. Available at: http://www.medscape.com/viewarticle/749515_1 Accessed June 18, 2018.
9 Gravante G, Delogu D, Giordan N, et al. The Use of Hyalomatrix PA in the Treatment of Deep Partial-Thickness Burns. Jour Burn Care Res. 2007;28(2):269-74.
10 Tam J, Wang Y, Farinelli WA, et al. Fractional Skin Harvesting: Autologous Skin Grafting without Donor-site Morbidity. Plastic and Reconstructive Surgery Global Open. 2013;1(6):e47. Available at: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4174164/ . Accessed June 18, 2018.
11 Kadam D. Novel expansion techniques for skin grafts. Indian Journal of Plastic Surgery. 2016;49(1):5-15. Available at: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4878244/ . Accessed June 18, 2018.
12 Kim PJ, Attinger CE, Bigham T, et al. Clinic-Based Debridement of Chronic Ulcers Has Minimal Impact on Bacteria. Wounds 2018;30(5):114–119. Available at: http://www.woundsresearch.com/article/clinic-based-debridement-chronic-ulcers-has-minimal-impact-bacteria . Accessed June 18, 2018.